ZNF31 Inhibitors
Chemical inhibitors of ZNF31 can effectively modulate its activity by targeting various signaling pathways and cellular processes that regulate this protein. Chelerythrine and GF109203X, both protein kinase C (PKC) inhibitors, can inhibit the phosphorylation of ZNF31, thus preventing its activation and subsequent regulatory functions. Similarly, the MEK inhibitors PD98059 and U0126 can impede the ERK pathway, which is known to play a role in modulating the activity of transcription factors, including ZNF31. By halting MEK activity, these inhibitors can suppress the downstream signaling that may affect ZNF31's regulatory impact on gene expression.
Moreover, the PI3K inhibitors LY294002 and Wortmannin can inhibit the PI3K/Akt pathway, which is crucial for the regulation of various transcription factors. These inhibitors can indirectly lead to reduced activity of ZNF31 by preventing the activation of downstream targets within this pathway. In a different signaling route, SP600125, a JNK inhibitor, and SB203580, inhibiting the p38 MAPK, can decrease ZNF31 activity by altering the regulatory influence of these kinases on ZNF31. Additionally, MG132, a proteasome inhibitor, can lead to the accumulation of ubiquitinated proteins, which may include ZNF31, thereby impeding its function. SN-38 affects DNA processes that influence ZNF31's role in gene regulation. Lastly, Rapamycin targets mTOR signaling, affecting protein synthesis and cell growth, which can indirectly lead to reduced activity of ZNF31 due to the broader effects on cellular growth signals. ICG-001 disrupts Wnt signaling by binding to CREB-binding protein, which may also alter ZNF31's activity due to changes in the signaling environment. Together, these chemicals can modulate the activity of ZNF31 through various biological pathways and mechanisms.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a potent inhibitor of protein kinase C (PKC), a family of enzymes that can phosphorylate ZNF31, potentially altering its function. By inhibiting PKC, chelerythrine indirectly prevents the phosphorylation of ZNF31, thus inhibiting its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which is upstream of the ERK pathway. ZNF31 activity can be regulated by ERK-mediated signaling. The inhibition of MEK, therefore, inhibits the ERK pathway, which can lead to a decrease in ZNF31 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which is part of the PI3K/Akt pathway that can regulate transcription factors including ZNF31. By inhibiting PI3K, LY294002 can suppress the activation of downstream targets, thereby inhibiting ZNF31 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, a kinase that may be involved in the signaling pathways that regulate ZNF31. Inhibition of JNK can reduce the regulatory influence on ZNF31, leading to a functional inhibition of ZNF31's activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The p38 MAPK pathway can influence various transcription factors, including ZNF31. Inhibition of p38 MAPK by SB203580 can lead to a decrease in ZNF31 activity as part of the cascading effects of this pathway. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins, potentially including ZNF31. This accumulation can indirectly inhibit ZNF31's function by disrupting its degradation and turnover processes. | ||||||
SN 38 | 86639-52-3 | sc-203697 sc-203697A sc-203697B | 10 mg 50 mg 500 mg | $119.00 $342.00 $883.00 | 19 | |
SN-38 is the active metabolite of the topoisomerase inhibitor irinotecan, which can interfere with DNA replication and transcription processes. By altering the transcriptional landscape, SN-38 can indirectly inhibit ZNF31's ability to regulate gene expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor like LY294002 but with a different chemical structure. It similarly leads to the functional inhibition of ZNF31 by suppressing PI3K/Akt pathway activation and its downstream effects on transcription factors. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a component of the mTOR signaling pathway that regulates protein synthesis and cell growth. By inhibiting mTOR, Rapamycin can lead to a reduction in ZNF31 activity due to the broader effects on cellular growth signals. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a chemically distinct MEK inhibitor, akin to PD98059. It contributes to the functional inhibition of ZNF31 by blocking MEK and subsequently the ERK pathway, which may affect ZNF31 regulatory functions. | ||||||